[MeMed in Med Tech News] Testing times: Combatting antibiotic misuse and antimicrobial resistance

Kfir Oved, chairman, co-founder and CTO of MeMed Diagnostics, writes about the development of its new technology aiming to combat antibiotic misuse and antimicrobial resistance (AMR).

Read more here.

The post [MeMed in Med Tech News] Testing times: Combatting antibiotic misuse and antimicrobial resistance appeared first on OurCrowd Blog.

OurCrowd Blog

[MeMed in The Times of Israel] MeMed partners with Italy’s DiaSorin to commercialize bacteria vs virus test

MeMed Diagnostics, a Haifa-based firm that develops diagnostic solutions to monitor the body’s immune state, said it will partner with Italian diagnostic firm DiaSorin to commercialize a test that is able to distinguish between bacterial and viral infections.

Read more here.

The post [MeMed in The Times of Israel] MeMed partners with Italy’s DiaSorin to commercialize bacteria vs virus test appeared first on OurCrowd Blog.

OurCrowd Blog

[MeMed in GlobeNewsWire] Prospective Study Finds Potential Utility of MeMed’s Host Immune Technology for Personalizing Treatment of Severe COVID-19 Patients

Researchers at Israel’s Rabin Medical Center (comprised of Beilinson and Hasharon Hospitals) in collaboration with MeMed, have published prospective data on the potential utility of the analysis of IP-10, a host immune biomarker, in managing the care and treatment of patients with severe COVID-19 infection.

Read more here.

The post [MeMed in GlobeNewsWire] Prospective Study Finds Potential Utility of MeMed’s Host Immune Technology for Personalizing Treatment of Severe COVID-19 Patients appeared first on OurCrowd Blog.

OurCrowd Blog

[MeMed in NoCamels] MeMed Receives CE Mark for Advanced Diagnostic Tech

Israeli medical diagnostics startup MeMed Diagnostics has received CE Mark clearance for its pioneering diagnostic test MeMed BV and point-of-need platform MeMed Key.

Founded in 2009, MeMed has built a diagnostic tool for distinguishing between bacterial and viral infections like the coronavirus. The company is now also developing a diagnostics test for early detection of viruses and the prediction of potential patient deterioration.

Read more here.

The post [MeMed in NoCamels] MeMed Receives CE Mark for Advanced Diagnostic Tech appeared first on OurCrowd.

OurCrowd

[MeMed in CTech] MeMed Receives Regulatory Green Light for Test that can Greatly Reduce Antibiotics Prescriptions

Israeli health company MeMed Diagnostics Ltd., which developed a test that can identify whether an infection was caused by a virus or bacteria thus significantly reducing the use of antibiotics for treatment, has received regulatory approval to put its rapid test, which can provide results within 15 minutes, on the Israeli and European market.

Read more here.

The post [MeMed in CTech] MeMed Receives Regulatory Green Light for Test that can Greatly Reduce Antibiotics Prescriptions appeared first on OurCrowd.

OurCrowd

[MeMed in Globes] MeMed to predict which COVID-19 patients will worsen

MeMed Diagnostics is known mostly for developing devices and tests that can rapidly distinguish between certain bacteria and viruses, based on the immune system’s response, mainly in order to prevent unnecessary use of antibiotics

Read more here.

The post [MeMed in Globes] MeMed to predict which COVID-19 patients will worsen appeared first on OurCrowd.

OurCrowd